Beta-lactam and Beta-lactamase Inhibitors Market

?-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related ?-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to ?-lactams is primarily because of bacterially produced ?-lactamase enzymes that hydrolyze the ?-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum ?-lactamase inhibitors that work against many problematic ?-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.
Beta-lactam and Beta-lactamase Inhibitors Market aims to provide a comprehensive presentation of the global market for Beta-lactam and Beta-lactamase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Beta-lactam and Beta-lactamase Inhibitors. Beta-lactam and Beta-lactamase Inhibitors Market contains market size and forecasts of Beta-lactam and Beta-lactamase Inhibitors in global, including the following market information:
Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Beta-lactam and Beta-lactamase Inhibitors Market Sales, 2018-2023, 2024-2029, (M Units)
Global top five Beta-lactam and Beta-lactamase Inhibitors companies in 2022 (%)
The global Beta-lactam and Beta-lactamase Inhibitors market was valued at US$ 29150 million in 2022 and is projected to reach US$ 33070 million by 2029, at a CAGR of 1.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share. The market include Asia Pacific, Europe and North America, with a share of 33%, 32% and 28%. cephalosporins accounted for 28% and penicillins accounted for 17%. The product is mainly used in intravenous and oral, with a share of 65% and 35%.
We surveyed the Beta-lactam and Beta-lactamase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Beta-lactam and Beta-lactamase Inhibitors Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, by Type, 2022 (%)
Penicillins
Cephalosporins
Carbapenems
Monobactams
Combinations
Global Beta-lactam and Beta-lactamase Inhibitors Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, by Application, 2022 (%)
Oral
Intravenous
Global Beta-lactam and Beta-lactamase Inhibitors Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Beta-lactam and Beta-lactamase Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Beta-lactam and Beta-lactamase Inhibitors revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Beta-lactam and Beta-lactamase Inhibitors revenues share in global market, 2022 (%)
Key companies Beta-lactam and Beta-lactamase Inhibitors sales in global market, 2018-2023 (Estimated), (M Units)
Key companies Beta-lactam and Beta-lactamase Inhibitors sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis (Sandoz)
TEVA
Merck
AbbVie (Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
Wockhardt
Lupin Limited
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice
Outline of Major Chapters:
Chapter 1: Introduces the definition of Beta-lactam and Beta-lactamase Inhibitors, market overview.
Chapter 2: Global Beta-lactam and Beta-lactamase Inhibitors market size in revenue and volume.
Chapter 3: Detailed analysis of Beta-lactam and Beta-lactamase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Beta-lactam and Beta-lactamase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Beta-lactam and Beta-lactamase Inhibitors capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.